Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors1. Issue 9 (2nd September 2015)

• Record Type: Journal Article
• Authors: Elliott, Richard J. R.; Jarvis, Ashley; Rajasekaran, Mohan B.; Menon, Malini; Bowers, Leandra; Boffey, Ray; Bayford, Melanie; Firth-Clark, Stuart; Key, Rebekah; Aqil, Rehan; Kirton, Stewart B.; Niculescu-Duvaz, Dan; Fish, Laura; Lopes, Filipa; McLeary, Robert; Trindade, Ines; Vendrell, Elisenda; Munkonge, Felix; Porter, Rod; Perrior, Trevor; Springer, Caroline; Oliver, Antony W.; Pearl, Laurence H.; Ashworth, Alan; Lord, Christopher J.
• Is Part Of: MedChemComm. Volume 6:Issue 9(2015:Sep.)
• Page Start: 1687
• Page End: 1692
• Publication Date: 2015-09-02
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c5md00210a
• Languages: English
• ISSNs: 2040-2503

Abstract

<abstract abstract-type="toc"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <graphic position="anchor" id="ga" xlink:href="ark:/27927/pgj2qrkxzwv" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink" />The tankyrase proteins (TNKS, TNKS2) are attractive anti-cancer drug targets, particularly as inhibition of their catalytic activity has been shown to antagonise oncogenic WNT signalling.</p> </abstract>